EISAI EYES ALZHEIMER'S MARKET

Japan's fourth-largest pharmaceutical company, Eisai, successfully resubmitted to the FDA a new drug application targeting its popular Alzheimer's drug Aricept to new markets. Eisai was rebuffed last year, when its application was rejected by the regulatory agency for technical deficiencies. The company submitted a corrected application this past December, and the FDA announced its acceptance of that application on Monday. Aricept is the world's most widely prescribed drug for treating Alzheimer's patients, though it's only for those with mild to moderate symptoms of the disease.

Yahoo News (http://biz.yahoo.com/fool/060215/114001192302.html?.v=2)